Drug Enforcement Administration
FDA to Require Supply of Mail-back Envelopes for Outpatient-dispensed Opioids
Examination of In-home Disposal Products also Planned; Notes on New DEA Registration Requirements On April 3, 2023, the U.S. Food and Drug Administration announced it is requiring manufacturers of opioid analgesics dispensed in outpatient settings (which includes home hospice care) to make prepaid mail-back envelopes available to outpatient pharmacies and other dispensers as an additional […]
Read MoreDEA Proposes Rules to Govern Post-PHE Prescribing of Controlled Substances via “Telehealth”
On Friday, February 24, 2023, the Drug Enforcement Administration (DEA) released proposed rules intended to govern the prescribing of controlled substances via telemedicine for application at the end of the COVID-19 Public Health Emergency (PHE). The proposed rule — — Telemedicine Prescribing of Controlled Substances When the Practitioner and the Patient Have Not Had a […]
Read MoreImportant Policy Developments on Hospice and Opioids
The opioid crisis continues to be a main focus of activities in Congress, within the Trump administration, among policymakers in Washington, D.C. and in the states. Efforts by all of these players have the potential to impact hospice care. Following is a summary of recent important activities in this area. DEA working to address drug […]
Read More